Charles River Laboratories offers Protein characterization, biosafety, PK/TK, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The website explicitly offers PROTAC and molecular glue screening, including HiBiT, proteomics, ternary-complex structures, ADME/DMPK, in vivo formulations, and safety services.
The website separately lists polymorph, hydrate, and solvate identification and salt screening services.
Protein characterization, biosafety, PK/TK, immunogenicity and biomarkers
Specialist contract research/testing services
Program / service
Target / indication
Representative stage
Evidence & scope
Chemistry toolbox, degradation assays, structure determination, and in vivo support
Program-dependent / not disclosed · Determined by the collaboration program
Platform / services
This record does not claim platform-wide human validation
Solid-state R&D capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Services / platform
Not applicable; not a human clinical program
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
The four-week proof-of-concept plan is target-dependent, not a guarantee for every program.
Public sources confirm service availability. Sample suitability, scope of work, pricing, turnaround time, success criteria, and the quality system require direct confirmation.
This record describes service capabilities, not the clinical progress of a drug candidate or an independent validation of service success rates.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
